

CLAIMS:

1. Use of a compound in the manufacture of a medicament for the treatment of hyperuricemia, wherein the compound has the structure:



or a pharmaceutically acceptable salt, or tautomer thereof.

2. Use of a compound in the manufacture of a medicament for reducing serum uric acid levels, wherein the compound has the structure:




or a pharmaceutically acceptable salt, or tautomer thereof.

3. The use of either of claims 1 or 2, wherein the compound is the sodium salt.
4. The use of any one of claims 1 to 3 in combination with allopurinol.
5. The use of any one of claims 1 to 3 in combination with febuxostat.


CLAIMS:

1. A compound for use as a medicament in the treatment of hyperuricemia or reducing serum uric acid, wherein the compound has the structure:



or a pharmaceutically acceptable salt, solvate, or tautomer thereof.

2. A compound for use as a medicament in reducing serum uric acid levels, wherein the compound has the structure:




or a pharmaceutically acceptable salt, solvate, or tautomer thereof.

3. The use of either of claims 1 or 2, wherein the compound is the sodium salt.

4. The use of any one of claims 1 to 3 in combination with allopurinol.


5. The compound for use of any one of claims 1 to 3 in combination with febuxostat.

6. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and a compound having the structure:



or a pharmaceutically acceptable salt, solvate, or tautomer thereof.

7. The pharmaceutical composition of claim 6, wherein the compound is the sodium salt.
8. The pharmaceutical composition of either of claims 6 or 7 adapted for oral use as discrete units.
9. The pharmaceutical composition of claim 6, further comprising a second agent effective for the treatment of gout.
10. The pharmaceutical composition of claim 9, wherein the second agent is a URAT 1 inhibitor, a xanthine oxidase inhibitor, a xanthine dehydrogenase, or a xanthine oxidoreductase inhibitor.
11. The pharmaceutical composition of claim 9, wherein the second agent is selected from allopurinol, febuxostat, FYX-051, or combinations thereof.
12. The pharmaceutical composition of claim 6, further comprising allopurinol.
13. The pharmaceutical composition of claim 6, further comprising febuxostat.
14. A pharmaceutically acceptable salt of a compound having the structure:



15. The pharmaceutically acceptable salt of claim 14, wherein the pharmaceutically acceptable salt is the sodium salt.